S-adenosyl-L-methionine (SAMe), cannabidiol (CBD), and kratom in
psychiatric disorders: Clinical and mechanistic considerations
Researchers have recently unveiled the benefits and challenges of utilizing cannabidiol (CBD) in the treatment of psychiatric disorders. CBD has been FDA approved for rare epileptic disorders in the United States and has been recognized for its anxiolytic effects. Dosing CBD can be difficult due to various consumption methods, different products offering ratios of CBD: THC (tetrahydrocannabinol) and terpene contents, all of which cause different effects. Along with anxiolytic effects, the anti-inflammatory effects of CBD have also been well documented, acting through various biological mechanisms. Although THC may not be positively recognized for its psychoactive properties, CBD has been documented by major studies to have anxiolytic and antipsychotic effects with added neuroprotective and anticonvulsant effects. The author concludes that due to the minimal side-effects associated with CBD psychiatrists should seriously consider recommending CBD to patients.
CBD has fallen into a more of a gray area than THC or cannabis in general as it appears to be widely accepted due to its wide availability yet some overarching associations still think poorly of its use. For example, the National Collegiate Athletic Association (NCAA) explicitly prohibits the use of THC and explains that, while not banned, student-athletes should be hesitant to use CBD products as it increases their risk of testing positive for THC and a healthy athlete should have no reason to utilize CBD anyway. Patients are recommended to seriously discuss their CBD use with a physician and do their research to determine how CBD is received by their places of work or other regulatory bodies they engage in.
The study is available for review or download here:
View more studies like this in the CED Foundation Archive: http://bit.ly/drcaplan